Zotarolimus
From Wikipedia, the free encyclopedia
|
Zotarolimus
|
|
| Systematic (IUPAC) name | |
| 1,18-Dihydroxy-19,30-dimethoxy-12-[2-(3-methoxy-4-tetrazol-1-yl-cyclohexyl)-1-methyl-ethyl]-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-aza-tricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | ? |
| Chemical data | |
| Formula | C52H79N5O12 |
| Mol. mass | ? |
| Synonyms | (42S)-42-Deoxy-42-(1H-tetrazol-1-yl)-rapamycin |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Zotarolimus (INN) is an immunosupressant. It is a semi-synthetic derivative of rapamycin.

